key: cord-0866990-sxffciav authors: Uskoković, Vuk title: Nanomedicine for the poor: a lost cause or an idea whose time has yet to come? date: 2021-05-14 journal: Nanomedicine DOI: 10.2217/nnm-2021-0024 sha: 012f518590730274750fe8acd95e552d70cbd45e doc_id: 866990 cord_uid: sxffciav The most effective COVID-19 vaccines, to date, utilize nanotechnology to deliver immunostimulatory mRNA. However, their high cost equates to low affordability. Total nano-vaccine purchases per capita and their proportion within the total vaccine lots have increased directly with the GDP per capita of countries. While three out of four COVID-19 vaccines procured by wealthy countries by the end of 2020 were nano-vaccines, this amounted to only one in ten for middle-income countries and nil for the low-income countries. Meanwhile, economic gains of saving lives with nano-vaccines in USA translate to large costs in middle-/low-income countries. It is discussed how nanomedicine can contribute to shrinking this gap between rich and poor instead of becoming an exquisite technology for the privileged. Two basic routes are outlined: (1) the use of qualitative contextual analyses to endorse R&D that positively affects the sociocultural climate; (2) challenging the commercial, competitive realities wherein scientific innovation of the day operates. sculpted figures, the more lustrous and exquisite character of the latter material made art made out of it, as in the works by Michelangelo and Donatello, more transcendent in nature. Innovations in medical technology have, likewise, had their say in shaping human values and modes of communication. Take biomaterials, for example: their extensive application leads to the dream about a bionic man, which may bring with it more computerized, if not purely perfunctory modes of communication. The lifesaving quality of prosthetics notwithstanding, many of the dystopian sci-fi auteurs have elaborated on this Promethean adoption of inhumane traits by human characters who have been turned into cyborgs [7, 8] . Nanomedicine per se, however, is a step up on the ladder of technical finesse compared with medicine alone. From its inception to this day, it has connoted the use of the most advanced technological tools for medical ends, for which reason discussions over its socioeconomic effects are of critical importance, even though they are thoroughly missing from today's discourse. Still, some examples of these effects can be proposed here. For one, a medical nanotechnology such as nanoparticles as contrast agents in radiographic imaging promotes clinical diagnostic modalities and a specific infrastructure and workforce tied with them. It also implicitly promotes the representation of the patient in geometric terms rather than as entangled pathways of biochemical reactions, which diagnostic chemical assays would naturally lead to. In contrast, a nanotechnology such as nanoparticles for targeted drug delivery facilitates a flexible and more decentralized network of medical points of care, gravitating more toward pharmacy practice as opposed to the reliance on massive medical instrumentation. Yet another example can be that of nanoparticles usable in genomic sequencing and gene expression analyses such as qPCR, which might lead to the reaffirmation of the premises of personalized medicine, along with its specific, but also isolationistic connotations. Personalized medicine, we know, can create obstacles for drug development, similar to that associated with the rare diseases, which large biotech companies find less financially rewarding to invest in compared with universal drugs, be they called aspirin, remdesivir, remeron or something else. Therefore, it becomes apparent how the birth and the fosterage of a new technology can change the socioeconomic aspects of the social system in which it is applied, notwithstanding the complexity of the network of causes and effects surrounding it, severely oversimplified in the aforementioned examples. So how can science and technology, including that pertaining to the field of nanomedicine, contribute to the narrowing of the detrimental gap between the rich and the poor? The starting point should be the awakening of the awareness of their influence on social equality, the deepening of which through comprehensive qualitative and quantitative analyses may lead to choices empowered by rational arguments. On one hand, being more accessible to the poor, inexpensive technologies are a natural healer of this notorious gap. However, it would be too simplistic to assume that minimization of the costs of resources, of production methods, of storage and administration are the only criteria needed to be satisfied to make technologies universally affordable. This is because this would only devalue the hi-tech philosophy which developed countries have worked hard to have the liberty to pursue. It would also be an extension of the materialistic economic paradigm that all the poor need is to increase their wealth [9] , which is a view that can be valid only if and when it gets complemented with analytical perspectives that take into account the cultural, ecological, humanistic and, why not, spiritual corollaries of the economic growth. Therefore, the overall zeitgeist and the broad contexts of application should be considered before bringing about the decision as to what constitutes a scientific method in favor of social equity and what is an approach with an adverse effect on it. Advocating nanomaterials such as nanocellulose, carbon dots or calcium phosphate (CaP) nanoparticles as medical materials for healing the social inequality gap only because they are comparatively inexpensive and impose a negligible ecological footprint is thus insufficient and needs to be supplemented with other types of inquiry. The use of CaP, for example, as a means for bridging the gap between the rich and the poor has aesthetic connotations that may resonate with cultures other than the western and thus go beyond sheer economic considerations. The idiosyncrasy of CaP among similar bioceramics [10] , its biogenic proliferation despite the intrinsic structural weaknesses [11] , and its chemical resemblance to the skeletal foundations of our bodies [12] can carry such aesthetic connotations. CaP is also a material whose popularity is evenly distributed across the globe, meaning that the sole act of engaging in its research may be sufficient to bring people from various cultures together. This is in contrast with the more exclusionary technologies, which leave the researchers with limited resources behind and contribute to widening the gap of inequality [13] . In general, small, adaptable technologies that resonate with the local cultures and are more smoothly implementable by them are particularly desirable here in comparison with the hefty medical tools, not only because of the infrastructure compatibility issues and the costs of production, installation, training and/or maintenance, but also because today's rapid replacements on the pedestal of state-of-the-art instrumentation lead to incertitude about the duration of their currency. Consequently, rapid successions on the conveyer belt of innovation in the developed world are double-edged swords: they may bring about certain benefits, but are also prone to only further aggravate the existing gap between the rich and the poor. The width of the inequality gap has a destabilizing social influence, making the system vulnerable under a slightest stress. This has become obvious in these days when the world is gripped by a deadly pandemic. The inability to curb the spread of infection regardless of the measures in place has insinuated profuse connections between people, even when these connections seem nonexistent. It has reminded the developed world that the burden of infectious diseases that plagues the daily life of many poor countries in the form of malaria or tuberculosis is only a whisker away [14] . It has also demonstrated how connected various aspects of a society are, as by affecting people's health, SARS-CoV-2 has put pressure not only on the systems of healthcare, but on everything else too, from limiting opportunities for scientific and other work to posing challenges for interpersonal communication to giving rise to various political schisms. Logically, in the geopolitically divided world of 2020, too focused on short-term interests to be able to consider the ecosphere as a network where everything is, more or less, connected to everything else, a concerted global commitment needed to effectively resolve a communicable disease pandemic such as COVID-19 has been thoroughly lacking. Correspondingly, deliberation over the case of vaccines for COVID-19 can be instructive here by shedding more light on this relationship between nanotechnologies and social equity. On one hand, the fact that the vaccines BNT162b1 (Pfizer-BioNTech) and mRNA-1273 (Moderna) are the first to be approved and administered both in the countries of their origin and globally may act as a beacon of hope for both the socially aware scientist looking after closing this gap and the general scientist in the nanomedical field, considering that out of nine COVID-19 vaccines approved by 19 January 2021 and many more being on the way, these two are the only nano-vaccines, utilizing phospholipid nanoparticles as adjuvants and as delivery vehicles for immunostimulatory mRNA [15] . Nanoparticles, of course, have had a long history of use as adjuvants [16] , even though traditional vaccines usually resort to simpler materials as boosters of the immune recognition of the antigens, such as alum, as in traditional tetanus and hepatitis B vaccines, inulin, as in some flu vaccines, or monophosphoryl lipid A, as in Cervarix. However, for the negatively charged and rather unstable mRNA, highly susceptible to proteolysis, to be endocytosed and translated into an antigenic protein, the right form of delivery is crucial, and this is where nanoparticles come to play as essential ingredients of these two vaccine formulations [17] . Therefore, the high price of these two mRNA vaccines is partly due to the use of mRNA encoding for the receptor-binding domain of the SARS-CoV-2 spike protein as the immunogen and partly due to the use of a nanoparticle carrier, but a significant contributor to the production cost also comes in the form of the nanotechnology integrating both of these ingredients into a drug delivery platform capable of achieving an effective intracellular transfer and transfection. Therefore, it should not surprise that the bottleneck in the mass production of mRNA vaccines for COVID-19, which significantly hampered the early immunization campaign, has come from the limited capacity to produce the lipid nanoparticles as carriers for the antigenic ribonucleic acids. A major positive aspect of these novel mRNA vaccines is the relative ease with which the sequence of nucleotides in the immunogenic molecule could be altered using a simple oligo synthesizer, as opposed to the more laborious process of changing the amino acid sequence in protein vaccines, making the former potentially more effective against a pandemic where the viral agent rapidly creates new variants through mutation, as it is the case with SARS-CoV-2 [18] . It is too early to know whether this instant sequence building approach utilizing critical but short genetic codes will fare well against the rapidly mutating SARS-CoV-2 virus or the duration of the protection would be mediocre compared with the more traditional exposure to inactivated whole virus. In a worst case scenario, a constant reproduction of new vaccines would be necessitated to keep up with the new emerging virus variants and although this approach might benefit the vaccine producer, it may not necessarily benefit the people. Irrespective of these uncertainties, the method is unequivocally commendable for the rapid antigenic design that it facilitates. Its success serves as an implicit call for continued research on advanced nanotechnologies for controlled and targeted drug delivery, which is, of course, badly needed in a world where most local infections are treated with systemic antibiotics, a method as preposterous as the hypothetical treating of a malarial mosquito outbreak in the Mudzi region of Zimbabwe by deploying pesticide-spraying airplanes over every corner of the planet and having people in Patagonian prairies and Siberian steppes cough up the toxins. In fact, the better protection against the SARS-CoV-2 infection achieved by BNT162b1 and mRNA-1273 than by more traditional vaccines may be expected to expand the interest in nano-vaccines, and one example may be a recently reported vaccine candidate in the form [25] . Most data points were collected from the Duke Global Health Innovation Center COVID-19 Launch and Scale Speedometer. Some data points were corrected by the author, e.g., Switzerland and Serbia, and some were added, e.g., Qatar. Countries with domestically produced vaccines, including China, Russia, UK and USA, have not been included in the analysis for bias concerns. Average percentage of COVID-19 nano-vaccines purchased by middle-income countries (US$1000 US$13,000 GDP per capita) by the end of 2020 relative to the total number of vaccines in their procured stocks (B). The total COVID-19 vaccine purchases by the poor countries (GDP per capita